# Marengo Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/marengo-therapeutics

- Industry: Biotechnology
- Headquarters: Cambridge, US
- Website: www.marengotx.com
- Total disclosed funding: $39M
- Latest round: Series A (Jan 3, 2017)
- Investors on record: 1

## About

Marengo Therapeutics, Inc. develops innovative therapeutic solutions for cancer and other diseases using proprietary TCR-targeting antibodies to enhance the immune response against malignancies.Founded in 2015 and headquartered in Cambridge, US, Marengo Therapeutics, Inc. specializes in creating therapeutic solutions through TCR-targeting antibodies. The company has completed 2 deals, with the latest funding round occurring on November 8, 2021, where it raised USD 80 mn in Seed funding led by Apple Tree Partners. CEO Zhen Su is at the helm, driving the company’s vision and strategy.Marengo Therapeutics focuses on developing first-in-class TCR-targeting antibodies aimed at modulating T cell subsets to activate the human immune system. Their products are designed to enhance the immune response against various cancers, catering to hospitals, oncology clinics, and research institutions across North America and Europe, with a focus on the US and select EU markets. The company’s approach to cancer treatment seeks to provide long-lasting protection from disease by advancing immuno-oncology solutions.Marengo Therapeutics generates revenue through the direct sale of its TCR-targeting antibodies, often under clinical trial agreements that may lead to commercialization. The company engages in B2B relationships with healthcare providers, who procure these products for patient treatments. Its pricing strategies are aligned with industry standards, reflecting the specialized nature of the biotech sector, and are designed to meet the increasing demand for advanced cancer therapies.Following the USD 80 mn raised in November 2021, Marengo Therapeutics, Inc. plans to utilize this funding to advance its research and development efforts, particularly in expanding its pipeline of TCR-targeting antibodies. The company aims to launch new products as it enhances its offerings and seeks entry into new markets, specifically focusing on expanding its presence in Europe and the US by 2023.

## Funding rounds

- Series A, Jan 3, 2017, $39M — Apple Tree Partners

## Investors

- Apple Tree Partners (https://capitalatlas.ai/funds/apple-tree-partners) — Series A